IL21R
Interleukin-21 receptor
Also known as: CD360, IL21R_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HBE5
- Gene
- IL21R
- Ensembl
- ENSG00000103522
- Chromosome
- 16
- Canonical length
- 538 aa
- Protein class
- Cancer-related genes, CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins
- Subcellular location
- Plasma membrane,Cytosol
OverviewNCBI Gene
The protein encoded by this gene is a cytokine receptor for interleukin 21 (IL21). It belongs to the type I cytokine receptors, and has been shown to form a heterodimeric receptor complex with the common gamma-chain, a receptor subunit also shared by the receptors for interleukin 2, 4, 7, 9, and 15. This receptor transduces the growth promoting signal of IL21, and is important for the proliferation and differentiation of T cells, B cells, and natural killer (NK) cells. The ligand binding of this receptor leads to the activation of multiple downstream signaling molecules, including JAK1, JAK3, STAT1, and STAT3. Knockout studies of a similar gene in mouse suggest a role for this gene in regulating immunoglobulin production. Three alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2010]
Canonical amino-acid sequenceUniProt
538 residues, UniProt reviewed canonical sequence.
>Q9HBE5|IL21R
1 MPRGWAAPLL LLLLQGGWGC PDLVCYTDYL QTVICILEMW NLHPSTLTLT WQDQYEELKD
61 EATSCSLHRS AHNATHATYT CHMDVFHFMA DDIFSVNITD QSGNYSQECG SFLLAESIKP
121 APPFNVTVTF SGQYNISWRS DYEDPAFYML KGKLQYELQY RNRGDPWAVS PRRKLISVDS
181 RSVSLLPLEF RKDSSYELQV RAGPMPGSSY QGTWSEWSDP VIFQTQSEEL KEGWNPHLLL
241 LLLLVIVFIP AFWSLKTHPL WRLWKKIWAV PSPERFFMPL YKGCSGDFKK WVGAPFTGSS
301 LELGPWSPEV PSTLEVYSCH PPRSPAKRLQ LTELQEPAEL VESDGVPKPS FWPTAQNSGG
361 SAYSEERDRP YGLVSIDTVT VLDAEGPCTW PCSCEDDGYP ALDLDAGLEP SPGLEDPLLD
421 AGTTVLSCGC VSAGSPGLGG PLGSLLDRLK PPLADGEDWA GGLPWGGRSP GGVSESEAGS
481 PLAGLDMDTF DSGFVGSDCS SPVECDFTSP GDEGPPRSYL RQWVVIPPPL SSPGPQASLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL21R can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.53
- Highest tissue expression
- 23 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 23 nTPM
- tonsil: 17 nTPM
- thymus: 13 nTPM
- appendix: 11 nTPM
- bone marrow: 7.1 nTPM
- spleen: 5.2 nTPM
Single-cell type
- nk-cells: 109 nCPM
- t-cells: 97 nCPM
- thymic myoid cells: 65 nCPM
- cdc: 42 nCPM
- pdcs: 36 nCPM
- innate lymphoid cells: 27 nCPM
Immune cell
- non-classical monocyte: 27 nTPM
- memory CD8 T-cell: 14 nTPM
- naive B-cell: 14 nTPM
- gdT-cell: 14 nTPM
- T-reg: 11 nTPM
- NK-cell: 9.4 nTPM
Brain region
- pons: 9.1 nTPM
- cerebral cortex: 8.6 nTPM
- midbrain: 6.9 nTPM
- medulla oblongata: 6.2 nTPM
- hypothalamus: 6.1 nTPM
- white matter: 5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL21R.
Disease | AllUniProt
Conditions IL21R is implicated in, by any mechanism.
- Immunodeficiency 56 (IMD56) MIM:615207
Disease | GeneticClinVar
11 pathogenic / likely-pathogenic of 445 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Cryptosporidiosis-chronic cholangitis-liver disease syndrome
ReferencesPubMed · IEDB
Publications for IL21R from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Altered Circulating Follicular T Helper Cell Subsets and Follicular T Regulatory Cells Are Indicators of a Derailed B Cell Response in Lupus, Which Could Be Modified by Targeting IL-21R.
2022 · Int J Mol Sci · RCR 1.2 · 16 citations - pSTAT3: a target biomarker to study the pharmacology of the anti-IL-21R antibody ATR-107 in human whole blood.
2013 · J Transl Med · RCR 0.4 · 15 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.21
- gnomAD pLI
- 1
- gnomAD missense Z
- 0.75
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- cytokine receptor activity
- transmembrane signaling receptor activity
- interleukin-21 receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL21R as an antibody target. Whether an autoantibody or antibody against IL21R could matter depends on whether native IL21R is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL21R is annotated at the cell surface, where native IL21R is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label IL21R as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...